Bristol Myers Squibb

Health Care Pharmaceuticals New York City, New York Last filing Feb 11, 2026 · FY2025

                    Revenue
                    FY2025
                
$48.2B
                    3y CAGR +1.4%
                    
                    P27
                    
                    n/a
                    
                    Net income
                    FY2025
                
$7.1B
                    Net margin +14.6%
                    
                    P61
                    
                    n/a
                    
                    Total assets
                    FY2025
                
$90.0B
                    ROA +7.8%
                    
                    P66
                    
                    n/a
                    
                    Operating cash flow
                    FY2025
                
$14.2B
                    FCF margin +26.7%
                    
                    P94
                    
                    n/a

19 yrs · FY2007–FY2025 8 filed · 0 derived · 1 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Year-over-year change per cell; first column has no prior.

Balance Sheet

Assets, liabilities, and equity

29 accounts · 1 year

Total assets $90.0B

Total liabilities $71.5B

Shareholders equity $18.5B

Account	2025	Trend
Assets
Cash and Cash Equivalents	—
Short Term Investments	—
Accounts Receivable	—
Inventory	—
Other Current Assets	—
Total Current Assets	—
Property,Plant and Equipment	—
Goodwill	—
Intangible Assets	—
Deferred Tax Assets	—
Other Noncurrent Assets	—
Total Assets	—
Liabilities
Accounts Payable	—
Current Portion of Long Term Debt	—
Other Current Liabilities	—
Total Current Liabilities	—
Long Term Debt	—
Deferred Tax Liabilities	—
Other Noncurrent Liabilities	—
Total Liabilities	—
Equity
Preferred Stock	—
Common Stock	—
Additional Paid In Capital	—
Retained Earnings	—
Treasury Stock	—
Accumulated Other Comprehensive Income	—
Total Stockholders Equity	—
Noncontrolling Interest	—
Total Liabilitiesand Equity	—

Income Statement

Revenue, expense, and profitability

12 accounts · 1 year

Revenue $48.2B

Operating income Not reported

Net income $7.1B

Account	2025	Trend
IncomeStatement
Revenues Total Revenue	—
Expenses Cost of Revenue	—
Expenses Research and Development	—
Expenses Selling,General and Administrative	—
Other Income Expense Other Income/expense	—
Other Income Expense Income Before Tax	—
Income Tax Income Tax Expense	—
net Income Other Items Below Tax	—
net Income net Income	—
net Income Comprehensive Income	—
Earnings Per Share Basic Eps	—
Earnings Per Share Diluted Eps	—

Cash Flow Statement

Operating, investing, and financing flows

22 accounts · 1 year

Operating cash flow $14.2B

Investing cash flow $-4.1B

Financing cash flow $-10.3B

Account	2025	Trend
CashFlow
Operating Activities net Income	—
Operating Activities Depreciation and Amortization	—
Operating Activities Stock Based Compensation	—
Operating Activities Deferred Income Taxes	—
Operating Activities Changes In Operating Assets and Liabilities	—
Operating Activities Other Non Cash Items	—
Operating Activities net Cash From Operating Activities	—
Investing Activities Capital Expenditures	—
Investing Activities Business Acquisitions	—
Investing Activities Purchases of Investments	—
Investing Activities Proceeds From Sale of Investments	—
Investing Activities Other Investing Activities	—
Investing Activities net Cash From Investing Activities	—
Financing Activities Proceeds From Debt	—
Financing Activities Repayment of Debt	—
Financing Activities Repurchase of Common Stock	—
Financing Activities Dividends Paid	—
Financing Activities Proceeds From Stock Issuance	—
Financing Activities Other Financing Activities	—
Financing Activities net Cash From Financing Activities	—
Cash Reconciliation Effect of Exchange Rate On Cash	—
Cash Reconciliation net Change In Cash	—

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 1 year

Ratio	2025
Profitability
Gross margin	+71.1%
Operating margin	—
Net margin	+14.6%
FCF margin	+26.7%
Growth
Revenue CAGR (3y)	+1.4%
Returns
ROE	+38.2%
ROA	+7.8%
ROIC	—
Liquidity
Current ratio	1.26x
Quick ratio	0.92x
Leverage
D/E	3.87x
Interest coverage	—
Efficiency
Asset turnover	0.54x
Cash conversion cycle	+63d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Bristol Myers Squibb

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history